| Literature DB >> 25333798 |
Thomas Grönthal1, Arshnee Moodley2, Suvi Nykäsenoja3, Jouni Junnila4, Luca Guardabassi2, Katariina Thomson5, Merja Rantala1.
Abstract
INTRODUCTION: The purpose of this study was to describe a nosocomial outbreak caused by methicillin resistant Staphylococcus pseudintermedius (MRSP) ST71 SCCmec II-III in dogs and cats at the Veterinary Teaching Hospital of the University of Helsinki in November 2010 - January 2012, and to determine the risk factors for acquiring MRSP. In addition, measures to control the outbreak and current policy for MRSP prevention are presented.Entities:
Mesh:
Year: 2014 PMID: 25333798 PMCID: PMC4198203 DOI: 10.1371/journal.pone.0110084
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1The monthly cumulative incidence of all MRSPs and MRSPs displaying the outbreak antibiogram (MRSP ST71) among patients of the Small Animal Hospital of Helsinki University from January 2010 to December 2012.
In late 2011 a small cluster of ST45 among hospitalized patients contributed to an increase in incidence. From January 2012 onwards the great majority of new MRSP findings have been detected in screening targeted to risk patients on admission. In December 2012 the increase was not due to a cluster, but was due to the detection of different types of MRSPs mainly in patients belonging to risk groups.
Variables analyzed from cases and controls during the MRSP outbreak in the Small Animal Hospital of Helsinki University between 2010 and 2011.
| Species (dog/cat) | Emergency surgery (during weekend/evening/night) | Aminopenicillin medication given |
| Age (years) | Length of anesthesia (min) |
|
| Gender |
| Cephalosporin medication given |
| Breed |
|
|
| Weight (kg) |
|
|
|
|
|
|
| Skin lesions of any cause | Antimicrobial medication given | Proton pump inhibitor (PPI) given |
| Surgical procedure |
|
|
Severity was judged by the author (TG) on a scale of 1 to 5 after reviewing the patient record on admission and was based on the guidelines provided by the American Society of Anesthesiologists.
The same patient might have had several visits or courses of medication, therefore the cumulative number of days for these variables was recorded until the first positive MRSP specimen (cases), or latest negative MRSP specimen (controls), see text for details.
Enrofloxacin was the only fluoroquinolone used for these patients.
Figure 2An epidemic curve showing new MRSP ST71 cases during the outbreak in 2010–2012 at the Small Animal Hospital of Helsinki University.
The outbreak period was between November 2010 and January 2012, after which the follow-up period was started. A: hospital closed for 2 days for cleaning and disinfection, B: establishment of cohort ward, C: nurse responsible for hospital hygiene appointed, D: hospital closed for 5 days for cleaning and disinfection, E: veterinarian appointed as infection control officer. S: Screening of hospitalized patients, H: environmental swabs taken.
Figure 3Dendrogram of 47 MRSP isolates with the outbreak antibiogram (see text).
Staphylococcus pseudintermedius ATCC 49444 is displayed as a control. *Further characterized by multilocus sequence typing and SCCmec-typing.
Nosocomial infections (n = 27) caused by the MRSP outbreak strain (ST71, SCCmec II–III) in the Small Animal Hospital of Helsinki University between 2010 and 2011.
| Infection type | Number of infections |
| Surgical site infections (total) | 19 |
| Required surgical revision | 3 |
| Involved orthopedic devices | 7 |
| Others (uncomplicated) | 9 |
| Other wound infections | 3 |
| Otitis | 1 |
| Bite wound | 2 |
| Dermatitis | 1 |
| Cystitis complicated by uroliths | 1 |
Some cases required removal of surgical devices and revision.
Patient had orthopedic surgery and several visits to the hospital, otitis was subsequently diagnosed.
Both patients presented with severe bite wounds; after prolonged hospital stay MRSP was cultured from the wound.
Patient presented with pneumonia, autoimmune myositis and dermal vasculitis; later developed MRSP infection on the skin lesion.
Colonization with MRSP preceded the cystitis.
The current risk based classification of patients at the Small Animal Hospital of Helsinki University and resulting measures.
| Classification | Criteria (any of the following) | Example of measures |
| High risk patients | MRSP-positive | Treated in cohort ward |
| Has been hospitalized >24 hours and has signs of a hospital acquired | Barrier nursing | |
| infection | Surgery at the end of the day | |
| Disinfection of facilities | ||
| Infection sites cultured | ||
| Standard precautions | ||
| Medium risk patients | Has a history of recurrent ear or skin infection | Screened for MRSP |
| Has a history of prolonged or numerous hospital visits or visits at | Treated in separate rooms | |
| other veterinary clinics | reserved for medium risk | |
| Has a history of prolonged or numerous antimicrobial treatments | patients | |
| Has been exposed to a patient with MRSP | Surgery at the end of the day | |
| Has had surgery elsewhere and has a surgical site infection | Standard precautions | |
| Has a suppurative wound infection | Infection sites cultured | |
| Low risk patients | All other patients | All other rooms |
| Standard precautions |
*Includes hand disinfection, hygienic work routine, and use of protective clothing in case of dirty procedures.
Risk factors associated with acquisition of MRSP during the outbreak in the Small Animal Hospital of Helsinki University between 2010 and 2011.
| Univariable logistic regression | Multivariable logistic regression | |||||||
| Binary variables | MRSP-pos | MRSP-neg | Unadjusted OR | Wald | Adjusted OR | Wald | ||
| ( | ( | (95% CI) |
| (95% CI) |
| |||
| n | % | n | % | |||||
|
| ||||||||
| Gender: M vs. F | 30 | 54.5 | 96 | 45.1 | 1.46 (0.80–2.66) | 0.212 | ||
| Species: dog vs. cat | 50 | 90.9 | 192 | 90.1 | 1.09 (0.39–3.06) | 0.864 | ||
|
| ||||||||
| Skin lesion | 49 | 89.1 | 85 | 39.9 | 12.40 (5.06–30.37) |
| 6.24 (2.30–16.97) |
|
| Antimicrobial treatment | 52 | 94.6 | 130 | 61.0 | 11.07 (3.33–36.79) |
| 3.80 (1.04–13.92) |
|
| Surgical procedure | 45 | 81.8 | 67 | 31.5 | 9.81 (4.65–20.70) |
| ||
| Cephalosporin treatment | 21 | 38.2 | 24 | 11.3 | 5.10 (2.54–10.26) |
| ||
| Enrofloxacin treatment | 18 | 32.7 | 33 | 15.5 | 2.70 (1,3–5.2) |
| ||
| Severity (1 vs. others) | 46 | 85.5 | 8 | 14.5 | 2.84 (1.3–6.4) |
| ||
| Aminopenicillin treatment | 34 | 61.8 | 93 | 43.7 | 2.09 (1.14–3.85) |
| ||
| Treatment in ICU | 41 | 74.6 | 126 | 59.2 | 2.02 (1.03–3.95) |
| ||
| Proton pump inhibitor treatment | 36 | 65.5 | 114 | 53.5 | 1.65 (0.89–3.06) | 0.115 | ||
| Orthopedic vs. soft tissue surgery | 20 | 44.4 | 20 | 30.3 | 1.84 (0.83–4.08) | 0.132 | ||
| Other antimicrobial treatment | 12 | 21.8 | 32 | 15.0 | 1.58 (0.75–3.33) | 0.229 | ||
| Emergency surgery | 6 | 13.6 | 9 | 13.4 | 1.02 (0.33–3.13) | 0.976 | ||
OR = Odds Ratio, CI = Confidence Interval.